Uncategorized

Endoscopy activity and cancer detection was slower to recover in gastric cancers, such as colorectal cancer (CRC), after the COVID-19 pandemic, with cancer detection slower than endoscopy activity to recover, according to a study published in Heliyon.1 Maintaining cancer services in future waves of the pandemic should be the focus in the future. Gastrointestinal diseases,…

The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. This time, the agency is considering limiting these immunotherapies’ use in stomach cancer and esophageal cancer. The FDA will hold an Oncologic Drugs Advisory Committee (ODAC) meeting Sept. 26 to consider whether approvals for checkpoint inhibitors in advanced gastric and…

Abstract: Microsatellite instability (MSI) has been widely acknowledged as an important factor regulating tumor intrinsic biological behavior and affecting the survival of gastric cancer patients. Here, we firstly identified the RARB as a gene associated with MSI gastric cancer. RARB was downregulated in human gastric cancer tissues compared to paired paracancerous tissues, Knockdown of RARB…

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Read More >

The recent application of targeted and immuno-oncology drugs to treat gastric cancer has significantly changed the outcome of inoperable gastric cancer. In the past, conventional chemotherapy for gastric cancer consisted of only cytotoxic antitumor drugs. Recently, however, it has become possible to add targeted or immuno-oncology drugs to cytotoxic antitumor drugs, depending on the “biomarkers”…

Gastric cancer, a significant global health challenge, is characterized by a complex transition from inflammation-induced premalignant lesions to malignancy. The quest for early diagnosis and prevention is impeded by the intricate biological shifts that mark this journey, highlighting an urgent need for a deeper dive into the underlying the multi-level and dynamic features Read More…

AstraZeneca and Daiichi Sankyo‘s antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received conditional approval from the China National Medical Products Administration (NMPA) for gastric cancer. The approval allows Enhertu to be used as a single agent for adults with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction…

(Reuters) -Britain’s health regulator said on Wednesday it has approved Japan-based Astellas Pharma’s therapy to treat a type of gastric cancer. The monoclonal antibody, which can attach itself to certain cancer cells and destroy them, was approved in combination with a standard chemotherapy for adults with cancer in the stomach or the junction where the…

The Association for Clinical Oncology (ASCO) is applauding the Senate Appropriations Committee for its bipartisan support of federal cancer research in the fiscal year (FY) 2025 Labor, Health and Human Services, Education, and Related Agencies spending bill. For FY 2025, the Senate is allocating $48.851 billion for the National Institutes of Health (NIH), a $1.77…

Treatment with EO-3021 (SYSA1801) produced promising preliminary data in a small cohort of patients with advanced, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) cancers expressing Claudin 18.2 (CLDN18.2), according to dose-escalation findings from a phase 1 trial (NCT05980416).1 Among 15 patients with evaluable gastric or GEJ cancers, 7 (47%) had CLDN18.2 expression in at…